The role of hematological parameters in predicting tumor grade and stage in renal cell carcinoma patients undergoing nephrectomy
DOI:
https://doi.org/10.18203/2349-2902.isj20262463Keywords:
Hematological parameters, Renal cell carcinoma, PCT, PLR, RDW, HPRAbstract
Background: The aim of this study is to evaluate the role of hematological parameters in predicting Fuhrman grade and tumor stage in renal cell carcinoma patients undergoing nephrectomy.
Methods: All patients newly admitted in the Department of Genitourinary Surgery in Kozhikode Medical College with a diagnosis of renal cell carcinoma from 01 August 2020 to 31 July 2021 were included after taking informed consent and considering the inclusion and exclusion criteria.
Results: Hematological parameters such as red blood cell distribution width (RDW), haemoglobin to platelet ratio (HPR), procalcitonin (PCT) and platelet to lymphocyte ratio (PLR) when correlated with the grade of cases, RDW and PLR were seen increased in high grade tumours. RDW and PLR showed statistically significant correlation with a p value of <0.001 for RDW and 0.02 for PLR. An RDW above 14.2 and PLR more than 140.69 is likely to be predictive of high Fuhrman grade. ROC curve was plotted and the mean RDW, PLR, PCT cut-off values of the patients for FG and T stage were 12.8%, 130.7, 0.24% and 13.8%, 166.01, 0.19% respectively. RDW, PLR, PCT, HPR were analyzed for any correlation for predicting whether the tumor be limited to kidney or extending outside kidney. Only RDW showed a statistically significant result with p value 0.02 and it suggests that RDW above 14.52 is suggestive of a tumor limited to kidney.
Conclusions: We conclude that when hematological parameters such as RDW and PLR were correlated with grade of the tumor and RDW with the stage of the tumor. HPR and PCT didn’t show significant relation with grade of tumor.
References
Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11(3):79-87.
Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75(1):74-84.
Fest J, Ruiter R, Mulder M, Koerkamp BG, Ikram MA, Stricker BH, et al. The systemic immune-inflammation index is associated with an increased risk of incident cancer: a population-based cohort study. Int J Cancer. 2020;146(3):692-8.
Prabawa IPY, Bhargah A, Liwang F, Tandio DA, Tandio AL, Lestari AAW, et al. Pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as predictive hematological markers in cervical cancer. Asian Pac J Cancer Prev. 2019;20(3):863-8.
Seles M, Posch F, Pichler GP, Gary T, Pummer K, Zigeuner R, et al. Blood platelet volume represents a novel prognostic factor in patients with nonmetastatic renal cell carcinoma and improves the predictive ability of established prognostic scores. J Urol. 2017;198(6):1247-52.
Partin AW, Dmochowski RR, Kavoussi LR, Peters CA. Campbell Walsh Wein Urology. 12th ed. Philadelphia: Elsevier; 2020.
Douglas B, Davaro F, May A, Siddiqui S, Hamilton Z. Clinical characteristics of renal cell carcinoma in patients under the age of 40. Urol Oncol. 2021;39(7):438.e23-30.
Peired AJ, Campi R, Angelotti ML, Antonelli G, Conte C, Lazzeri E, et al. Sex and gender differences in kidney cancer: clinical and experimental evidence. Cancers (Basel). 2021;13(18):4588.
Vasudev NS, Wilson M, Stewart GD, Adeyoju A, Cartledge J, Kimuli M, et al. Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort. BMJ Open. 2020;10(5):e035938.
Kisa E, Yucel C, Keskin MZ, Karabicak M, Yalcin MY, Cakmak O, et al. The role of hematological parameters in predicting Fuhrman grade and tumor stage in renal cell carcinoma patients undergoing nephrectomy. Medicina (Kaunas). 2019;55(6):287.
Yuk HD, Kang M, Hwang EC, Park JY, Jeong CW, Song C, et al; Korean Renal Cancer Study (KRoCS) Group. The platelet-to-lymphocyte ratio as a significant prognostic factor to predict survival outcomes in patients with synchronous metastatic renal cell carcinoma. Investig Clin Urol. 2020;61(5):475-81.
Qin C, Sun LJ, Cui L, Cao Q, Zhu J, Li P, et al. Application of the revised TNM staging system of clear cell renal cell carcinoma in eastern China: advantages and limitations. Asian J Androl. 2013;15(4):550-7.
Huszno J, Kolosza Z, Mrochem-Kwarciak J, Rutkowski T, Skladowski K. The role of neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, and platelets in the prognosis of metastatic renal cell carcinoma. Oncology. 2019;97(1):7-17.
Downloads
Published
How to Cite
Issue
Section
